Heart failure & cardiomyopathies
Apoptosis, a Useful Marker in the Management of Hot-Phase Cardiomyopathy?
Authors' conclusion
Apoptosis, rather than significant inflammation, was mostly prevalent in this case series of patients with 'hot-phase' presentation, especially in carriers of variants in cardiomyopathy-related genes.
Study context
- Population
- Patients hospitalised for suspected hot-phase cardiomyopathy who underwent endomyocardial biopsy and genetic testing, 2017–2022
- Participants
- 17 patients
- Outcome
- Histological findings at EMB: significant cardiac inflammation and apoptosis (TUNEL)
Methodological detailsconsecutive patients, two Italian centres, Median follow-up 18 months, Apoptosis confirmed with TUNEL assay
- Consecutive patients
- Two Italian centres
- Median follow-up 18 months
- Apoptosis confirmed with TUNEL assay
Main finding
As reported in the abstract
Significant cardiac inflammation (standard histological and immunohistochemical markers) at endomyocardial biopsy (EMB)
6
35%
Apoptosis at EMB
13
77%
Observational data: associations, not effects.
Original publication
Apoptosis, a Useful Marker in the Management of Hot-Phase Cardiomyopathy? Eur J Heart Fail. Published 27 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →